ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Actinium Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.32+0.19 (+16.81%)
Close on Oct 19, 2026
- Market cap
- $41.46M
- P/E (TTM)
- 3.7
- Dividend yield
- –
Share price
−$0.14 (−9.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Actinium Pharmaceuticals, Inc. reported revenue of $90.00K for fiscal 2025. Free cash flow was -$24.68M.
Revenue
$90.00K
FY2025
Operating income
$9.56M
TTM Q2 2026
Free cash flow
-$24.68M
FY2025
EPS, diluted
$0.36
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $41.46M
- P/E ratio
- 3.7
- Price to sales
- 460.63
- Price to book
- 1.37
- Dividend yield
- –
- Free cash flow yield
- -59.54%
Fundamentals
- Revenue
- $90.00K
- Net income
- $11.31M
- EPS, diluted
- $0.36
- Free cash flow
- -$24.68M
- Book value per share
- $0.96
- Diluted shares
- 31M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
$9.56M
Net income
$11.31M
EPS, diluted
$0.36
Free cash flow
–
Reported periodTrailing twelve months